| CAS No 64603-91-4 |
Isoxazolo[5,4-c]pyridin-3(2H)-one,4,5,6,7-tetrahydro-null |
Inquiry |
| CAS No 6425-66-7 |
Benzene,1,2-bis(bromomethyl)-4-nitro-null |
Inquiry |
| CAS No 64168-68-9 |
Spiro[1-azabicyclo[2.2.2]octane-3,2'-oxirane],hydrochloride (1:1)null |
Inquiry |
| CAS No 64190-52-9 |
1H-Indene-1-ethanol,octahydro-4-hydroxy-b,7a-dimethyl-, (bS,1R,3aR,4S,7aR)-null |
Inquiry |
| CAS No 641571-10-0 |
Nilotinib & its intermediatesnull |
Inquiry |
| CAS No 639089-54-6 |
Cyclopropanecarboxamide,N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-null |
Inquiry |
| CAS No 6393-40-4 |
3-Nitro-4-Aminobenzonitrilenull |
Inquiry |
| CAS No 639082-38-5 |
nullnull |
Inquiry |
| CAS No 637328-69-9 |
Tanogitrannull |
Inquiry |
| CAS No 635701-59-6 |
Merck SIP Agonistnull |
Inquiry |
| CAS No 635318-11-5 |
2-Thiabicyclo[3.1.0]hexane-4,6-dicarboxylicacid, 4-amino-, 2,2-dioxide, (1R,4S,5S,6S)-null |
Inquiry |
| CAS No 635305-47-4 |
1,3,2-Dioxaborolane,2-(3-chlorophenyl)-4,4,5,5-tetramethyl-null |
Inquiry |
| CAS No 63435-76-7 |
nullnull |
Inquiry |
| CAS No 635303-41-2 |
nullnull |
Inquiry |
| CAS No 63399-77-9 |
H-ALPHA-ME-D-PRO-OHnull |
Inquiry |
| CAS No 63283-36-3 |
Calcifediolnull |
Inquiry |
| CAS No 63399-74-6 |
nullnull |
Inquiry |
| CAS No 630386-06-0 |
nullnull |
Inquiry |
| CAS No 625097-31-6 |
nullnull |
Inquiry |
| CAS No 629664-81-9 |
3-(3,4-Difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethylazepino[4,5-b]indole-5-carboxylic acid 1-methylethyl esternull |
Inquiry |
| CAS No 624734-26-5 |
nullnull |
Inquiry |
| CAS No 624729-66-4 |
2-Naphthalenol,8-amino-1,2,3,4-tetrahydro-null |
Inquiry |
| CAS No 624733-88-6 |
1,5-Anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3-(trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]carbonyl]-3-(1-methylethyl)cyclopentyl]amino]-4-O-methyl-D-erythro-pentitolnull |
Inquiry |
| CAS No 623563-74-6 |
nullnull |
Inquiry |
| CAS No 620113-73-7 |
alpha-[[2-(4-Fluorophenoxy)-9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrilenull |
Inquiry |
